Peanut allergy immunotherapy - DBV Technologies

Drug Profile

Peanut allergy immunotherapy - DBV Technologies

Alternative Names: DBV 712; EPIT® Peanut; Viaskin Peanut

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DBV Technologies
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 22 Sep 2017 DBV Technologies completes the phase III PEPITES trial for Peanut hypersensitivity (In Children) in USA, Canada, Australia, Ireland and Germany (NCT02636699)
  • 31 Jul 2017 DBV Technologies initiates enrolment in a phase III trial for Peanut hypersensitivity (In children, In infants) in USA (Topical) (NCT03211247)
  • 10 Jul 2017 DBV Technologies plans to initiate a phase III trial in Peanut hypersensitivity (In children) in USA (NCT03211247)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top